These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 3825695)
21. Sensorimotor disturbances in Parkinson's disease: index finger test. Chouza C; Scaramelli A; Aljanati R; De Medina O; Caamaño JL; Lorenzo J; Romero S Adv Neurol; 1987; 45():339-43. PubMed ID: 3825707 [No Abstract] [Full Text] [Related]
22. Clinical features, diagnosis, and imaging of parkinsonian syndromes. Poewe W Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):333-8. PubMed ID: 8507902 [TBL] [Abstract][Full Text] [Related]
23. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease. Rascol O; Fabre N; Blin O; Poulik J; Sabatini U; Senard JM; Ané M; Montastruc JL; Rascol A Mov Disord; 1994 Jul; 9(4):437-40. PubMed ID: 7969211 [TBL] [Abstract][Full Text] [Related]
24. Clozapine withdrawal symptoms in a Parkinson's disease patient. Zesiewicz TA; Borra S; Hauser RA Mov Disord; 2002 Nov; 17(6):1365-7. PubMed ID: 12465085 [TBL] [Abstract][Full Text] [Related]
25. [Medical management and social status of elderly Parkinson patients]. Vieregge P; Körtke D; Meyer-Bornsen C Z Gerontol; 1994; 27(4):260-9. PubMed ID: 7975817 [TBL] [Abstract][Full Text] [Related]
26. Clinicopharmacological study of long-term Jumex + Dopaflex combination treatment in Parkinson's syndrome. Antóny M; Tóth G; Széplaki Z Ther Hung; 1982; 30(4):168-71. PubMed ID: 6821398 [No Abstract] [Full Text] [Related]
27. Motor response complications with chronic levodopa therapy. Chase TN; Fabbrini G; Juncos JL; Mouradian MM Adv Neurol; 1990; 53():377-81. PubMed ID: 2239478 [No Abstract] [Full Text] [Related]
34. CSF biopterin levels and clinical features of patients with juvenile parkinsonism. Furukawa Y; Nishi K; Kondo T; Mizuno Y; Narabayashi H Adv Neurol; 1993; 60():562-7. PubMed ID: 8420192 [No Abstract] [Full Text] [Related]
35. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures. Pahwa R; Lyons K; McGuire D; Silverstein P; Zwiebel F; Robischon M; Koller WC Mov Disord; 1997 Sep; 12(5):677-81. PubMed ID: 9380047 [TBL] [Abstract][Full Text] [Related]
36. [Trial use of L-dopa associated with a dopa-decarboxylase inhibitor in Parkinson's syndrome]. Carotti A; Tomassetti G; Lucciarini L; Barone G; Mugnai A Clin Ter; 1974 Jul; 70(1):9-15. PubMed ID: 4153252 [No Abstract] [Full Text] [Related]
37. Longitudinal study of the motor response to levodopa in Parkinson's disease. Clissold BG; McColl CD; Reardon KR; Shiff M; Kempster PA Mov Disord; 2006 Dec; 21(12):2116-21. PubMed ID: 17029259 [TBL] [Abstract][Full Text] [Related]
38. Parkinson's disease. Clarke C; Moore A Clin Evid; 2002 Dec; (8):1370-85. PubMed ID: 12603943 [No Abstract] [Full Text] [Related]
39. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease. Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P; Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842 [TBL] [Abstract][Full Text] [Related]
40. A case of levodopa-responsive camptocormia associated with advanced Parkinson's disease. Ho B; Prakash R; Morgan JC; Sethi KD Nat Clin Pract Neurol; 2007 Sep; 3(9):526-30. PubMed ID: 17805247 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]